Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

The use of biologics for uveitis associated with spondyloarthritis

Arepalli, Sruthia; Rosenbaum, James T.a,b

Current Opinion in Rheumatology: July 2019 - Volume 31 - Issue 4 - p 349–354
doi: 10.1097/BOR.0000000000000619
SPONDYLOARTHROPATHIES: Edited by Atul A. Deodhar
Buy

Purpose of review The term spondyloarthritis (SpA) encompasses a group of chronic inflammatory disorders of the joints, including ankylosing spondylitis, psoriatic arthritis, reactive arthritis, inflammatory bowel disease, juvenile SpA and undifferentiated SpA. These diseases can also present with uveitis, or intraocular inflammation, which can be controlled with biologics.

Recent findings Profound success has occurred with the tumor necrosis factor-α inhibitors infliximab and adalimumab, moderate success with certolizumab pegol and golimumab and less encouraging results with etanercept. Promising results have also been demonstrated with interleukin-17 (IL-17) antagonists, such as secukinumab ixekizumab or combined IL-12 and 23 medications, such as ustekinumab.

Summary In cases of uveitis that require long-term control, biologics are an emerging and valuable class of medications for these patients, and may provide avenues to control both their underlying SpA and uveitis manifestations.

aCasey Eye Institute

bDivision of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, Oregon, USA

Correspondence to James T. Rosenbaum, MD, Casey Eye Institute, Oregon Health & Science University, 3375 SW Terwilliger Blvd., Portland, OR 97239, USA. E-mail: rosenbaj@ohsu.edu

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.